January 22, 2019 by Randy Burt and Todd Huseby
A.T. Kearney, cannabidiol (CBD), legal cannabis-based products, Randy Burt, Todd Huseby
Business, January 21, 2019, Leading Headlines, Opinion, Retail News

Editor’s note: This is Part I of an article that ran in the 1/21/19 issue of CDR. As legal cannabis-based products continue to find their way to market, promising to redefine entire categories from health, beauty and wellness to food and beverage in their wake, most chain drug retailers are scrambling to calculate the impact
January 21, 2019 by Chain Drug Review
Affordable Care Act
January 21, 2019, News

WASHINGTON — Since becoming law in March 2010, the Patient Protection and Affordable Care Act, known more commonly as the ACA or Obamacare, has been a burr under the saddle of Republicans — and President Trump in particular. While some Americans embraced the ACA as a vehicle for them to get insurance and for its
January 21, 2019 by Chain Drug Review
Alex Gourlay, WBA
January 21, 2019, News

SAN FRANCISCO — During a fireside chat at the annual J.P. Morgan Healthcare Conference here earlier this month, Walgreens Boots Alliance (WBA) co-chief operating officer Alex Gourlay spoke to the number of partnerships the company has brought to the marketplace as well as the future of health care. WBA has always viewed vertical integration positively,
January 21, 2019 by Chain Drug Review
John Standley, Rite Aid
January 21, 2019, News

CAMP HILL, Pa. — Rite Aid Corp.’s flagging stock price notwithstanding, the chain has “great opportunities for growth,” chief executive officer John Standley said this month at the annual JP Morgan Healthcare Conference. Standley spoke less than a week after the New York Stock Exchange notified the retailer that it was no longer in compliance
January 21, 2019 by Chain Drug Review
Sears, Sears bankruptcy, Sears chairman Eddie Lampert
January 21, 2019, News

CHICAGO — At presstime, Sears Holdings Corp. chairman Eddie Lampert submitted a revised bid in a last-ditch attempt to save the retailer from liquidation. The new bid, $5 billion for the retailer through his hedge fund ESL Investments, is adding about $600 million to a prior bid that should help ESL clear bars to a
January 21, 2019 by Chain Drug Review
CVS, Ritzman Pharmacies
January 21, 2019, News

MEDINA, Ohio — CVS Health has acquired Ritzman Pharmacies and has plans to close almost all of its 20 Ohio stores and transfer the prescription files. Terms were not disclosed. Ritzman’s units in Akron and Berlin will be rebranded CVS Pharmacy. The Ritzman locations in Rittman, Shreve, Sugarcreek, Wooster-Milltown, Medina-River Styx, Millersburg, Barberton, Wadsworth, Norton,
January 21, 2019 by Chain Drug Review
cannabis, Shoppers Drug Mart
January 21, 2019, News

TORONTO — Shoppers Drug Mart (SDM) recently launched its online platform for the sale of medical cannabis, providing patients with a single, trusted source for all their cannabis therapy needs. The launch brings together Canada’s current e-commerce model for medical cannabis with the expert advice and counsel from trusted health care professionals. “As trusted medication
January 21, 2019 by Chain Drug Review
inventory management solutions, IRI
January 21, 2019, Opinion

CHICAGO — In recent years, a transforming economy and disruptive technology have converged to change the landscape of the consumer packaged goods industry. Today’s shoppers are far more sophisticated and demanding than ever, expecting a best in-store experience that includes having the shelves stocked properly so that the shoppers find the products they are looking
January 21, 2019 by Chain Drug Review
CVS-Aetna, Larry Merlo
January 21, 2019, News
SAN FRANCISCO — During a presentation at the 37th Annual J.P. Morgan Healthcare Conference here, CVS Health chief executive officer Larry Merlo talked about the efforts that have already taken place to integrate Aetna into its business. “While it’s only been six weeks, we are absolutely off and running,” Merlo said. He also announced that
January 21, 2019 by Jeffrey Woldt
Affordable Care Act, NPC, prescription drug prices
January 21, 2019, Opinion

Everyone recognizes that the high cost of health care in the U.S. is a chronic problem, the fallout from which is hurting patients, constraining providers and preventing the nation from marshalling adequate resources to address other essential needs. As noted in this space earlier this month, the Affordable Care Act, the legislation that governs the